AUS
NZ
UK
CA
USA
IND
Highlights
- Avita Medical reports 67% rise in Q1 revenue
- Net loss narrows, but share price sees steep dip
- Company maintains full-year growth and cash flow outlook
Avita Medical (ASX:AVH), a biotech firm dual-listed on the ASX and NASDAQ, reported a significant rise in first-quarter revenue, but this financial uplift wasn't reflected in the share price performance. Despite a 67% jump in revenue for the March quarter, the company’s stock dropped nearly 20% to AU$2.40 during early trading on the ASX200.
For the three months ending March, Avita Medical posted revenue of US$18.5 million, up from US$11.1 million in the same period last year. The company’s net loss narrowed to US$13.9 million from US$18.7 million, indicating improved operational efficiency. Gross profit margins, however, saw a slight dip, coming in at 84.7%, down from 86.4% year-on-year.
Avita reaffirmed its full-year guidance, expecting revenue growth of between 55% and 65%, totaling between US$100 million and US$106 million. It also projects free cash flow generation in the second half of the year, supporting a more sustainable financial trajectory.
The revenue growth was fueled by the launch of two new products—Recell Go mini and Cohealyx, a collagen-based dermal matrix. These product rollouts are part of the company’s broader strategy to transition from a service-based model to a product-driven approach. CEO Jim Corbett emphasized that this expanded portfolio has grown the company's addressable U.S. market from US$455 million to over US$3.5 billion.
This sharp market reaction—despite strong quarterly figures—highlights the often volatile nature of ASX200 biotech stocks. For investors exploring the broader landscape of Australian equities, dividend-focused strategies such as those involving ASX dividend stocks or broader index-focused investing in the ASX300 may provide a more stable outlook.
Avita Medical’s market pullback appears disconnected from its operational progress and future guidance, a pattern not uncommon in the high-growth biotech space where sentiment can swing sharply. As the company progresses with its U.S. product expansion and works toward cash flow positivity, market watchers may continue to monitor whether operational improvements translate into renewed investor confidence.
